HIF2 ODD-luciferase reporter: the most sensitive assay for HIF prolyl hydroxylase inhibitors


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

Reporters expressing fusion proteins of HIF2 and HIF3 C-terminal oxygen degradable domain (ODD) with the firefly luciferase, HIF2 ODD-luc and HIF3 ODD-luc, were constructed and briefly characterized. Stable neuroblastoma cell lines expressing either reporter were generated, and their response to the known HIF prolyl hydroxylase inhibitors: dimethyloxalylglycine, ciclopirox, and adaptaquin, was studied and compared with the HIF1 ODD-luc reporter. The HIF2 ODD-luc reporter exhibited the highest sensitivity: its response in absolute luminescence value was almost an order of magnitude higher than that of the HIF1 ODD-luc reporter. The new reporter can be used for a fine discrimination of enzyme inhibitors stabilizing HIF2, and further structural optimization of adaptaquin discovered earlier by using the HIF1 ODD-luc reporter. The higher sensitivity of HIF2 ODD-luc reporter could be most likely explained by the lower affinity of the endogenous enzyme for this HIF isoform in comparison with the two others, which also resulted in the increased efficiency of inhibitors under the reporter assay conditions.

About the authors

N. A. Smirnova

D. Rogachev Federal Scientific and Clinical Center of Pediatric Hematology, Oncology, and Immunology

Email: andrey.poloznikov@fccho-moscow.ru
Russian Federation, 1 ul. Samory Mashela, Moscow, 117997

A. I. Osipyants

D. Rogachev Federal Scientific and Clinical Center of Pediatric Hematology, Oncology, and Immunology

Email: andrey.poloznikov@fccho-moscow.ru
Russian Federation, 1 ul. Samory Mashela, Moscow, 117997

A. Yu. Khristichenko

D. Rogachev Federal Scientific and Clinical Center of Pediatric Hematology, Oncology, and Immunology

Email: andrey.poloznikov@fccho-moscow.ru
Russian Federation, 1 ul. Samory Mashela, Moscow, 117997

D. M. Hushpulian

D. Rogachev Federal Scientific and Clinical Center of Pediatric Hematology, Oncology, and Immunology

Email: andrey.poloznikov@fccho-moscow.ru
Russian Federation, 1 ul. Samory Mashela, Moscow, 117997

S. V. Nikulin

D. Rogachev Federal Scientific and Clinical Center of Pediatric Hematology, Oncology, and Immunology

Email: andrey.poloznikov@fccho-moscow.ru
Russian Federation, 1 ul. Samory Mashela, Moscow, 117997

T. A. Chubar

Department of Chemical Enzymology, Faculty of Chemistry, M. V. Lomonosov Moscow State University

Email: andrey.poloznikov@fccho-moscow.ru
Russian Federation, Build. 3, 1 Leninskie Gory, Moscow, 119991

A. A. Zakhariants

Innovation and High Technologies MSU Ltd

Email: andrey.poloznikov@fccho-moscow.ru
Russian Federation, 16 ul. Tsimlyanskaya, Moscow, 109451

V. I. Tishkov

Department of Chemical Enzymology, Faculty of Chemistry, M. V. Lomonosov Moscow State University; Innovation and High Technologies MSU Ltd

Email: andrey.poloznikov@fccho-moscow.ru
Russian Federation, Build. 3, 1 Leninskie Gory, Moscow, 119991; 16 ul. Tsimlyanskaya, Moscow, 109451

I. G. Gazaryan

D. Rogachev Federal Scientific and Clinical Center of Pediatric Hematology, Oncology, and Immunology; Department of Chemical Enzymology, Faculty of Chemistry, M. V. Lomonosov Moscow State University

Email: andrey.poloznikov@fccho-moscow.ru
Russian Federation, 1 ul. Samory Mashela, Moscow, 117997; Build. 3, 1 Leninskie Gory, Moscow, 119991

A. A. Poloznikov

D. Rogachev Federal Scientific and Clinical Center of Pediatric Hematology, Oncology, and Immunology

Author for correspondence.
Email: andrey.poloznikov@fccho-moscow.ru
Russian Federation, 1 ul. Samory Mashela, Moscow, 117997


Copyright (c) 2018 Springer Science+Business Media, LLC, part of Springer Nature

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies